STAT+: Roivant acquires drug for pulmonary hypertension from Bayer

For months, investors have been asking Roivant Sciences chief executive Matt Gline to reveal the next drug it planned to buy with some of the $6 billion made from last year’s Roche deal. On Tuesday, Gline obliged.

Roivant has acquired from Bayer, the German pharma company, an experimental drug called mosliciguat that will be developed as a treatment for certain types of pulmonary hypertension, a family of serious lung diseases in which high blood pressure affects the arteries in the lungs and causes damage to the heart. 

Bayer was paid $14 million upfront by Roivant for global rights to mosliciguat and will be eligible for another $280 million in milestone-based payments, plus royalties on sales, Roivant said.

Continue to STAT+ to read the full story…

Read Original Article: STAT+: Roivant acquires drug for pulmonary hypertension from Bayer »